EGFR and non-small cell lung carcinoma: Collectively, these rare NSCLC cases carrying EGFR exon 19 insertions and rare deletion mutations suggest that some patients with these mutations may have favorable and durable responses to afatinib, supplying important clinical proof that afatinib treatment should be chosen for this particular group of patients with mutations.